Kiora Pharmaceuticals, Inc. (KPRX) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2024
Loading P/E history...
KPRX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Kiora Pharmaceuticals, Inc. (KPRX) trades at a price-to-earnings ratio of 2.8x, with a stock price of $2.45 and trailing twelve-month earnings per share of $-1.96.
The current P/E is 13% below its 5-year average of 3.2x. Over the past five years, KPRX's P/E has ranged from a low of 2.0x to a high of 4.6x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, KPRX trades at a 87% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, KPRX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KPRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
KPRX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $74B | 17.1Lowest | 2.70Best | +8%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
KPRX Historical P/E Data (2024–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | $3.30 | $0.71 | 4.6x | +43% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $3.66 | $1.83 | 2.0x | -38% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $4.20 | $1.83 | 2.3x | -29% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $6.35 | $1.57 | 4.0x | +25% |
Average P/E for displayed period: 3.2x
See KPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KPRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKPRX — Frequently Asked Questions
Quick answers to the most common questions about buying KPRX stock.
Is KPRX stock overvalued or undervalued?
KPRX trades at 2.8x P/E, near its 5-year average of 3.2x. The 50th percentile ranking places valuation within normal historical bounds.
How does KPRX's valuation compare to peers?
Kiora Pharmaceuticals, Inc. P/E of 2.8x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is KPRX's PEG ratio?
KPRX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2024.